Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 676 to 700 of 797

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)	TA277	27 March 2013	27 March 2013
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	TA272	23 January 2013	23 January 2013
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)	TA273	23 January 2013	23 January 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma	TA268	12 December 2012	12 December 2012
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)	TA270	12 December 2012	12 December 2012
Dronedarone for the treatment of non-permanent atrial fibrillation	TA197	25 August 2010	1 December 2012
Mannitol dry powder for inhalation for treating cystic fibrosis	TA266	28 November 2012	28 November 2012
Ivabradine for treating chronic heart failure	TA267	28 November 2012	28 November 2012
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours	TA265	24 October 2012	24 October 2012
Alteplase for treating acute ischaemic stroke	TA264	26 September 2012	26 September 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	TA263	22 August 2012	22 August 2012
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	TA261	25 July 2012	25 July 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2	TA257	27 June 2012	27 June 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer	TA258	27 June 2012	27 June 2012
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine	TA260	27 June 2012	27 June 2012
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis	TA254	25 April 2012	25 April 2012
Pharmalgen for the treatment of bee and wasp venom allergy	TA246	22 February 2012	22 February 2012
Tocilizumab for the treatment of rheumatoid arthritis	TA247	22 February 2012	22 February 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy	TA242	25 January 2012	25 January 2012
Rituximab for the first-line treatment of stage III-IV follicular lymphoma	TA243	25 January 2012	25 January 2012
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults	TA245	25 January 2012	25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer	TA118	24 January 2007	1 January 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis	TA238	14 December 2011	14 December 2011
Fulvestrant for the treatment of locally advanced or metastatic breast cancer	TA239	14 December 2011	14 December 2011
Mifamurtide for the treatment of osteosarcoma	TA235	26 October 2011	26 October 2011

Results per page

10
25
50
All